Understanding TRT and Its Impact on Prostate Health: What You Need to Know

Written by Adam Maggio | Medically reviewed by Dr. Mitchell Ross, MD, ABAARM

Testosterone replacement therapy (TRT) improves symptoms of low testosterone without significantly increasing prostate cancer risk in men with normal prostate health. Careful screening and regular monitoring of PSA and prostate exams are essential to ensure safety during TRT.

# TRT and Prostate Health: What You Need to Know

Testosterone replacement therapy (TRT) has become an increasingly common treatment for men experiencing symptoms of low testosterone, such as fatigue, decreased libido, and reduced muscle mass. While TRT can offer significant benefits, concerns about its impact on prostate health remain a crucial consideration for many patients and clinicians alike. This article explores the relationship between TRT and prostate health, highlighting current evidence, practical protocols, and safety measures to help you make informed decisions.

---

Understanding TRT and Its Uses

What Is Testosterone Replacement Therapy?

Testosterone replacement therapy involves administering testosterone to men diagnosed with hypogonadism—a condition characterized by low testosterone levels confirmed through blood tests and clinical symptoms. TRT can be delivered via injections, gels, patches, or pellets, with dosages tailored to restore physiological testosterone levels.

Typical dosing for injectable testosterone formulations, such as testosterone cypionate or enanthate, ranges from 50 to 100 mg administered intramuscularly every 1 to 2 weeks. Transdermal gels often provide 25 to 100 mg daily, depending on the product and patient needs.

---

Prostate Health: The Basics

The Prostate and Its Function

The prostate is a small gland located below the bladder in men, playing a vital role in seminal fluid production. Prostate health becomes a concern primarily due to common conditions such as benign prostatic hyperplasia (BPH) and prostate cancer, both of which increase with age.

Why Is Prostate Health Important in TRT?

Testosterone is known to influence prostate tissue because it can be converted into dihydrotestosterone (DHT), a hormone that stimulates prostate growth. Historically, there has been concern that TRT might increase the risk of prostate enlargement or cancer progression, leading to caution in prescribing TRT to men with prostate issues.

---

Current Evidence: TRT and Prostate Cancer Risk

What Does the Research Say?

Contrary to earlier beliefs, recent large-scale studies and meta-analyses suggest that TRT does not significantly increase the risk of developing prostate cancer in men with normal prostate health. For example, a 2016 review published in European Urology reported no elevated incidence of prostate cancer in men undergoing TRT compared to control groups.

Moreover, TRT does not appear to accelerate the progression of prostate cancer in men who have been adequately treated and are under close medical supervision. Nonetheless, TRT is generally contraindicated in men with active or untreated prostate cancer.

TRT and PSA Levels

Prostate-specific antigen (PSA) is a protein produced by prostate cells, often used as a screening tool for prostate abnormalities. TRT can cause a mild, transient increase in PSA levels during the first 3 to 6 months of therapy. However, significant or sustained PSA elevations should prompt further evaluation to rule out prostate pathology.

---

Monitoring Prostate Health During TRT

Recommended Screening Protocols

Before initiating TRT, baseline prostate evaluation is essential. This typically includes:

  • Digital Rectal Exam (DRE): To assess prostate size and detect nodules.
  • PSA Testing: Baseline PSA level measurement.
  • Medical History Review: Assessing risk factors such as family history of prostate cancer or prior prostate conditions.

    • Ongoing Monitoring

    During TRT, regular follow-up is critical to ensure prostate health remains stable. Guidelines suggest:

  • PSA Testing: Every 3 months during the first year, then every 6 to 12 months thereafter.
  • DRE: Annually or as clinically indicated.
  • Symptom Assessment: Monitoring for urinary symptoms that may indicate BPH or other prostate issues.

    • If PSA rises above 1.4 ng/mL within the first year or increases by more than 0.75 ng/mL in any 12-month period, further investigation including urological referral and possible biopsy is warranted.

    ---

    Practical Guidelines for Safe TRT Use Regarding Prostate Health

    Patient Selection

  • TRT is appropriate for men with confirmed low testosterone and no evidence of prostate cancer.
  • Men with a history of treated prostate cancer may be candidates for TRT but require close specialist supervision.
  • Patients with elevated baseline PSA or abnormal DRE findings should undergo further evaluation before starting TRT.

    • Dosing and Administration

  • Tailor dosing to maintain testosterone levels within the mid-normal physiological range (typically 400-700 ng/dL).
  • Avoid supraphysiological dosing, which may increase risks to prostate and cardiovascular health.

    • Lifestyle and Additional Measures

  • Encourage regular exercise and a balanced diet to support overall prostate and metabolic health.
  • Avoid tobacco and excessive alcohol, which may exacerbate prostate risks.
  • Regular medical follow-up is essential for ongoing risk assessment and therapy optimization.

    • ---

    Conclusion

    Testosterone replacement therapy offers meaningful benefits for men suffering from hypogonadism, improving quality of life and physical function. Importantly, current scientific evidence indicates that TRT, when appropriately prescribed and monitored, does not